AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Adaptive Biotechnologies ... (ADPT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

8.35

-0.02 (-0.24%)

At close: Feb 20, 2025, 3:59 PM

8.49

1.74%

After-hours: Feb 20, 2025, 04:44 PM EST

undefined% (undefined)

Bid	8.02
Market Cap	1.23B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.08
PE Ratio (ttm)	-7.73
Forward PE	n/a
Analyst	Buy

Ask	9
Volume	1,382,727
Avg. Volume (20D)	1,455,808
Open	8.39
Previous Close	8.37
Day's Range	8.21 - 8.69
52-Week Range	2.28 - 8.95
Beta	undefined

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a cli...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 27, 2019

Employees 709

Stock Exchange NASDAQ

Ticker Symbol ADPT

Website https://www.adaptivebiotech.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 7.85% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Adaptive Biotechnologies Corporation is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-3.21%

Adaptive Biotechnologies shares are trading lower.... Unlock content with Pro Subscription

3 months ago

+11.51%

Adaptive Biotechnologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7.

News

1 week ago · zacks.com

Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 week ago · zacks.com

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

1 week ago · seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q4 2024 Results Conference Call February 11, 2025 4:30 PM ET Company Participants Karina Calzadilla - Head of IR & FP&A Chad Robins - CEO and Co-Fou...

1 week ago · zacks.com

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to ...

1 week ago · zacks.com

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.

1 month ago · zacks.com

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Here is how Adaptive Biotechnologies (ADPT) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.

1 month ago · zacks.com

Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?

Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre...

2 months ago · zacks.com

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

2 months ago · seekingalpha.com

Adaptive Biotechnologies: Making Some Progress

Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driv...